Patent ID: 11913073
Assignee: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  G  A | IPC A  C  G

Claim 0:
1. A method of treating a condition in a subject in need of belimumab comprising: administering a therapeutically effective amount of belimumab to the subject, wherein the subject has a decreased risk of progressive multifocal leukoencephalopathy (PML) due to an infection of the brain by John Cunningham virus (JCV), wherein the subject's decreased risk is associated with the absence of one or more genetic variations in the subject, wherein the subject has been tested for a presence of the one or more genetic variations with a genetic assay and has been identified as not having the one or more genetic variations; wherein the one or more genetic variations comprise a single nucleotide variation (SNV) in a syntaxin binding protein 2 (STXBP2) gene, wherein the SNV in a STXBP2 gene comprises chr19:7712287 G>C; wherein chromosome positions of the one or more genetic variations are defined with respect to UCSC hg19.